ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
22.95
+0.92 (4.18%)
At close: Feb 17, 2026, 4:00 PM EST
23.35
+0.40 (1.74%)
After-hours: Feb 17, 2026, 7:05 PM EST
ACADIA Pharmaceuticals Employees
As of December 31, 2024, ACADIA Pharmaceuticals had 654 total employees, including 653 full-time and 1 part-time employees. The number of employees increased by 56 or 9.36% compared to the previous year.
Employees
654
Change
56
Growth
9.36%
Revenue / Employee
$1,601,098
Profits / Employee
$399,349
Market Cap
3.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 654 | 56 | 9.36% | 653 | 1 |
| Sep 30, 2024 | 620 | 40 | 6.90% | 620 | 0 |
| Jun 30, 2024 | 630 | 90 | 16.67% | 630 | 0 |
| Mar 31, 2024 | 610 | 70 | 12.96% | 610 | 0 |
| Dec 31, 2023 | 598 | 85 | 16.57% | 597 | 1 |
| Sep 30, 2023 | 580 | 70 | 13.73% | 580 | 0 |
| Jun 30, 2023 | 540 | 0 | - | 540 | 0 |
| Mar 31, 2023 | 540 | 40 | 8.00% | 540 | 0 |
| Dec 31, 2022 | 513 | -1 | -0.19% | 511 | 2 |
| Sep 30, 2022 | 510 | -60 | -10.53% | 510 | 0 |
| Jun 30, 2022 | 540 | -70 | -11.48% | 540 | 0 |
| Mar 31, 2022 | 500 | -140 | -21.88% | 500 | 0 |
| Dec 31, 2021 | 514 | -87 | -14.48% | 512 | 2 |
| Sep 30, 2021 | 570 | -10 | -1.72% | 570 | 0 |
| Jun 30, 2021 | 610 | 40 | 7.02% | 610 | 0 |
| Mar 31, 2021 | 640 | 90 | 16.36% | 640 | 0 |
| Dec 31, 2020 | 601 | 98 | 19.48% | 601 | 0 |
| Sep 30, 2020 | 580 | 90 | 18.37% | 580 | 0 |
| Jun 30, 2020 | 570 | 93 | 19.50% | 570 | 0 |
| Mar 31, 2020 | 550 | 85 | 18.28% | 550 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 685 |
| TG Therapeutics | 374 |
| Liquidia | 170 |
| Arcellx | 163 |
| Centessa Pharmaceuticals | 114 |
| CG Oncology | 113 |
| Erasca | 103 |
| NewAmsterdam Pharma Company | 77 |
ACAD News
- 13 days ago - Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire
- 14 days ago - Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards - Seeking Alpha
- 15 days ago - Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union - Business Wire
- 5 weeks ago - ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - Business Wire
- 2 months ago - Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Business Wire
- 2 months ago - Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality - Seeking Alpha